Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego

Impact of Direct Acting Antivirals Uptake in Controlling Hepatitis C Epidemic and Modeling Interventions for Hepatitis C Elimination Among HIV-infected Persons in San Diego

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03551002

Enrollment

450

Registered

2018-06-11

Start date

2018-01-01

Completion date

2021-12-31

Last updated

2021-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis C, Hepatitis C, Chronic, HIV/AIDS

Keywords

HIV, Hepatitis C, Direct acting antivirals, Hepatitis C modeling

Brief summary

A retrospective and prospective study among people living with HIV (PLWH) that assesses hepatitis C (HCV) treatment uptake during periods before and after direct acting antivirals (DAA) introduction, and its impact on the HCV epidemic among PLWH.

Detailed description

A study that aims to quantify the state of DAA uptake and its impact on the HCV epidemic among PLWH in San Diego, and to characterize negative predictors of DAA treatment uptake among PLWH in San Diego. Retrospective and prospective data from UCSD Owen Clinic will be utilized to calculate HCV prevalence, primary incidence, and reinfection incidence. Using mathematical epidemic models, the study will assess levels of existing and scaled-up interventions necessary for HCV elimination from PLWH in San Diego.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

OTHER

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Any adult (≥ 18 years) HIV-infected patient attending the UCSD Owen Clinic * With history of acute or chronic HCV infection defined as having a detectable HCV viral load with or without a positive HCV antibody

Exclusion criteria

* With no history of or current HCV infection defined as having a negative HCV antibody from 2008 to 2020

Design outcomes

Primary

Measure	Time frame
Annual proportion of HIV-infected patients who initiate direct acting antivirals	2014-2020

Secondary

Measure	Time frame
Annual proportion of PLWH co-infected with HCV who are treatment naïve, previously treated with no sustained virologic response (SVR), or re-infected post-SVR	2008-2020
Annual HCV chronic prevalence, primary incidence, and reinfection incidence among HIV-infected patients	2008-2020

Other

Measure	Time frame
Estimated HCV prevalence and incidence among PLWH in San Diego using dynamic transmission modeling calibrated to epidemiological data from outcomes described above	2008-2030

Countries

United States

Contacts

Primary ContactEdward Cachay, MD, MAS

ecachay@ucsd.edu(619)543-3882

Outcome results